<DOC>
	<DOC>NCT02423889</DOC>
	<brief_summary>This is a prospective, single arm, phase II, multicentric study. It evaluates the acute and late toxicity after stereotactic radiotherapy in low risk prostate cancer patients. All participants receive a total dose of 36.25 Gy in 5 fractions, twice a week, 7.25 Gy per fraction.</brief_summary>
	<brief_title>Stereotactic Volumetric Radiotherapy in Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histology of prostate adenocarcinoma Age≥ 18 years Life expectancy≥ 10 years Clinical negative nodes (N0) No metastasis presence (M0) No previous pelvic radiation therapy Total PSA≤10 ng/ml Gleason score ≤ 6 T12 ≤ 3 positive biopsy at prostatic mapping Signed informed consent Positive nodes (N+) or metastatic disease (M+) Inflammatory bowel disease, collagen vascular disorders or active autoimmune disorders Anticoagulant treatment in progress Hip or pelvic presence of medical devices that could prevent a correct image acquisition Symptomatic haemorrhoidal disease Adverse reactions to iodinate or paramagnetic contrast media Previous malignant cancer, except basocellular skin tumour or other tumours healed since 5 years Previous pelvic radiotherapy Psychiatric disorder that preclude to obtain informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Hypofractionated radiotherapy</keyword>
	<keyword>SBRT</keyword>
</DOC>